98%
921
2 minutes
20
Heparanase is an endo-beta-glucuronidase, the only enzyme in mammals capable of cleaving heparan sulfate/heparin chains from proteoglycans. The oligosaccharides generated by heparanase present extensive biological functions since such oligosaccharides interact with adhesion molecules, growth factors, angiogenic factors and cytokines, modulating cell proliferation, migration, inflammation, and carcinogenesis. However, the regulation of heparanase activity is not fully understood. It is known that heparanase is synthesized as an inactive 65 kDa isoform and that post-translation processing forms an active 50 kDa enzyme. In the present study, we are interested in investigating whether heparanase is regulated by its own substrate as observed with many other enzymes. Wild-type Chinese hamster (Cricetulus griséus) ovary cells (CHO-K1) were treated with different doses of heparin. Heparanase expression was analyzed by Real-time PCR and flow cytometry. Also, heparanase activity was measured. The heparanase activity assay was performed using a coated plate with biotinylated heparan sulfate. In the present assay, a competitive heparin inhibition scenario was set aside. Exogenous heparin trigged a cell signaling pathway that increased heparanase mRNA and protein levels. The Wnt/beta-catenin pathway, judged by TCF-driven luciferase activity, seems to be involved to enhance heparanase profile during treatment with exogenous heparin. Lithium chloride treatment, an activator of the Wnt/beta-catenin pathway, confirmed such mechanism of transduction in vivo using zebrafish embryos and in vitro using CHO-K1 cells. Taken together the results suggest that heparin modulates heparanase expression by Wnt/beta-catenin.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11033-021-06348-3 | DOI Listing |
Semin Oncol
September 2025
Departments of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, New Jersey, USA. Electronic address:
Chimeric antigen receptor (CAR) T-cell therapy has changed how we treat blood cancers but hasn't worked as well for solid tumors like pancreatic ductal adenocarcinoma (PDAC), mainly because these tumors are very aggressive and resistant to regular treatments. This review critically examines peer-reviewed studies to chart the evolution of immunotherapy in PDAC, emphasizing the unique barriers to effective CAR T-cell treatment and emerging strategies to overcome them. CAR T-cells that focus on tumor-related markers like mesothelin, HER2, and MUC1 have shown promise in early research models.
View Article and Find Full Text PDFFASEB J
September 2025
LIENSs UMR 7266, CNRS-La Rochelle Université, La Rochelle, France.
Heparanase 1 (HPSE1) is a unique endoglycosidase responsible for the enzymatic cleavage of heparan sulfate, thereby playing important functions in cancer processes. In contrast, the structurally related Heparanase 2 (HPSE2) lacks catalytic activity and appears to counteract HPSE1 activities. However, contradictory observations in various pathologies highlight the need for a better understanding of the respective contributions of both heparanases.
View Article and Find Full Text PDFArterioscler Thromb Vasc Biol
August 2025
Department of Nephrology, Institute of Functional and Applied Anatomy, Hannover Medical School, Germany. (Y.B., S.T., N.S., S.R., A.A., H.S., Y.K., H.H.).
Background: Vessel-lining endothelial cells (ECs) rely on heparan sulfate (HS) proteoglycans to regulate vascular permeability and to maintain vascular homeostasis. Hpa2 (heparanase 2) is a little-known, nonenzymatic, HS-binding protein. We hypothesized major functions and thus characterized the role of endogenous Hpa2 in the vertebrate vascular system.
View Article and Find Full Text PDFFront Pharmacol
July 2025
Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Sepsis-associated lung injury (SALI) is a critical condition with high mortality. Current therapies are limited, necessitating novel approaches. This review highlights the potential of exogenous Specialized Pro-resolving Mediators (SPMs), including lipoxins, resolvins, protectins, and maresins, in mitigating SALI.
View Article and Find Full Text PDFAnticancer Agents Med Chem
August 2025
Anhui Provincial Engineering Research Center for Polysaccharide Drugs, Wuhu, Anhui, China.
Introduction: Cancer metastasis and associated thrombosis are significant contributors to cancerrelated mortality, necessitating therapeutic strategies that simultaneously address both issues. This study aimed to evaluate the dual anti-metastatic and anti-hypercoagulability properties of dHG-5, a low-molecular-weight fucosylated glycosaminoglycan derived from the sea cucumber Holothuria fuscopunctata.
Methods: The heparanase-inhibitory and anticoagulant effects of dHG-5 were assessed in vitro using biochemical assays.